This page shows the latest Piqray news and features for those working in and with pharma, biotech and healthcare.
Novartis has announced that Piqray (alpelisib) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in combination with Faslodex (fulvestrant) for the treatment of advanced ... The recommendation follows the
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
and Piqray (alpelisib) for breast cancer – that both have blockbuster sales potential.
Blockbuster potential for PI3K drug. Novartis has gained FDA approval for its PI3K inhibitor Piqray for advanced breast cancer, bucking the trend for the drug class in solid tumour therapy. ... The approval is for Piqray (alpelisib formerly BYL719)
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
No results were found
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...